Filtered By:
Procedure: Dialysis
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 32899 results found since Jan 2013.
Experimental Cardiorenal Syndrome Type 3: What Is Known so Far?
CONCLUSION: The findings may explain why AKI increases the risk of acute cardiac complications even if dialysis treatment has been initiated.PMID:35211213 | PMC:PMC8827225 | DOI:10.14740/jocmr4639
Source: Clin Med Res - February 25, 2022 Category: Research Authors: Daniel Patschan Benedikt Marahrens Monique Jansch Susann Patschan Oliver Ritter Source Type: research
Interventions for treating catheter-related bloodstream infections in people receiving maintenance haemodialysis
CONCLUSIONS: Currently, there is no available high certainty evidence to support one treatment over another for CRBSIs. The benefit of using ethanol lock treatment in combination with systemic antibiotics compared to systemic antibiotics alone for CRBSIs in patients receiving maintenance HD remains uncertain due to the very low certainty of the evidence. Hence, further RCTs to identify the benefits and harms of CRBSI treatment options are needed. Future studies should unify CRBSI and cure definitions and improve methodological design.PMID:35363884 | PMC:PMC8974891 | DOI:10.1002/14651858.CD013554.pub2
Source: Cochrane Database of Systematic Reviews - April 1, 2022 Category: General Medicine Authors: Beatriz M Almeida Daniel H Moreno Vladimir Vasconcelos Daniel G Cacione Source Type: research
Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults
CONCLUSIONS: Given the low-certainty evidence, we are uncertain whether intermittent locking with heparin results in fewer central venous catheter occlusions than intermittent locking with normal saline in adults. Low-certainty evidence suggests that heparin may have little or no effect on catheter patency duration. Although we found no evidence of differences in safety (CVC-related bloodstream infections, mortality, or haemorrhage), the combined studies were not powered to detect rare adverse events such as heparin-induced thrombocytopaenia. Further research conducted over longer periods would reduce the current uncertain...
Source: Cochrane Database of Systematic Reviews - July 18, 2022 Category: General Medicine Authors: Eduardo L ópez-Briz Vicente Ruiz Garcia Juan B Cabello Sylvia Bort-Mart í Rafael Carbonell Sanchis Source Type: research
Protein restriction for diabetic kidney disease
CONCLUSIONS: Dietary protein restriction has uncertain effects on changes in kidney function over time. However, it may make little difference to the risk of death and kidney failure. Questions remain about protein intake levels and compliance with protein-restricted diets. There are limited data on HRQoL and adverse effects such as nutritional measures and hyperglycaemic events. Large-scale pragmatic RCTs with sufficient follow-up are required for different stages of CKD.PMID:36594428 | PMC:PMC9809923 | DOI:10.1002/14651858.CD014906.pub2
Source: Cochrane Database of Systematic Reviews - January 3, 2023 Category: General Medicine Authors: Shimin Jiang Jinying Fang Wenge Li Source Type: research
Prostaglandins for adult liver transplanted recipients
CONCLUSIONS: Eleven trials evaluated prostaglandins in adult liver transplanted recipients. Based on low-certainty evidence, prostaglandins may reduce all-cause mortality up to one month; may cause little to no difference in serious adverse events, liver retransplantation, early allograft dysfunction, primary non-function of the allograft, and length of hospital stay; and may have a large reduction in the development of acute kidney injury requiring dialysis. We do not know the effect of prostaglandins on adverse events considered non-serious. We lack adequately powered, high-quality trials evaluating the effects of prosta...
Source: Cochrane Database of Systematic Reviews - August 4, 2023 Category: General Medicine Authors: Zubair Umer Mohamed Christi Titus Varghese Abish Sudhakar Lakshmi Kumar Unnikrishnan Gopalakrishnan Dinesh Balakrishnan Ramachandran Narayanamenon Surendran Sudhindran Source Type: research
Interventions for atypical haemolytic uraemic syndrome
CONCLUSIONS: When compared with historical data, terminal complement inhibition appears to offer favourable outcomes in patients with aHUS, based upon very low-quality evidence drawn from five single-arm studies. It is unlikely that an RCT will be conducted in aHUS and therefore careful consideration of future single-arm data as well as longer term follow-up data will be required to better understand treatment duration, adverse outcomes and risk of disease recurrence associated with terminal complement inhibition.PMID:33783815 | DOI:10.1002/14651858.CD012862.pub2
Source: Cochrane Database of Systematic Reviews - March 30, 2021 Category: General Medicine Authors: Dan Pugh Eoin D O'Sullivan Fiona Ai Duthie Philip Masson David Kavanagh Source Type: research
Interventions for weight loss in people with chronic kidney disease who are overweight or obese
CONCLUSIONS: All types of weight loss interventions had uncertain effects on death and cardiovascular events among overweight and obese adults with CKD as no studies reported these outcome measures. Non-surgical weight loss interventions (predominately lifestyle) appear to be an effective treatment to reduce body weight, and LDL cholesterol. Surgical interventions probably reduce body weight, waist circumference, and fat mass. The current evidence is limited by the small number of included studies, as well as the significant heterogeneity and a high risk of bias in most studies.PMID:33782940 | DOI:10.1002/14651858.CD013119.pub2
Source: Cochrane Database of Systematic Reviews - March 30, 2021 Category: General Medicine Authors: Marguerite M Conley Catherine M McFarlane David W Johnson Jaimon T Kelly Katrina L Campbell Helen L MacLaughlin Source Type: research
Altered dietary salt intake for people with chronic kidney disease
CONCLUSIONS: We found high certainty evidence that salt reduction reduced blood pressure in people with CKD, and albuminuria in people with earlier stage CKD in the short-term. If such reductions could be maintained long-term, this effect may translate to clinically significant reductions in CKD progression and cardiovascular events. Research into the long-term effects of sodium-restricted diet for people with CKD is warranted.PMID:34164803 | DOI:10.1002/14651858.CD010070.pub3
Source: Cochrane Database of Systematic Reviews - June 24, 2021 Category: General Medicine Authors: Emma J McMahon Katrina L Campbell Judith D Bauer David W Mudge Jaimon T Kelly Source Type: research
Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome
CONCLUSIONS: The included studies assessed antibiotics, bovine milk, and Shiga toxin inhibitor (Synsorb Pk) and monoclonal antibodies (Urtoxazumab) against Shiga toxin for secondary prevention of HUS in patients with diarrhoea due to STEC. However, no firm conclusions about the efficacy of these interventions can be drawn given the small number of included studies and the small sample sizes of those included studies. Additional studies, including larger multicentre studies, are needed to assess the efficacy of interventions to prevent development of HUS in patients with diarrhoea due to STEC infection.PMID:34219224 | DOI:1...
Source: Cochrane Database of Systematic Reviews - July 5, 2021 Category: General Medicine Authors: Aamer Imdad Samuel P Mackoff David M Urciuoli Tamkeenat Syed Emily E Tanner-Smith Dongmei Huang Oscar G Gomez-Duarte Source Type: research
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D
CONCLUSIONS: Among patients with CKD stages 3-4, anti-osteoporotic drugs may reduce the risk of vertebral fracture in low certainty evidence. Anti-osteoporotic drugs make little or no difference to the risk of clinical fracture and adverse events in moderate certainty evidence. Among patients with CKD stages 5 and 5D, it is uncertain whether anti-osteoporotic drug reduces the risk of clinical fracture and death because the certainty of this evidence is very low. Anti-osteoporotic drug may slightly improve the BMD at the lumbar spine in low certainty evidence. It is uncertain whether anti-osteoporotic drug improves the BMD ...
Source: Cochrane Database of Systematic Reviews - July 7, 2021 Category: General Medicine Authors: Takashi Hara Yasukazu Hijikata Yukiko Matsubara Norio Watanabe Source Type: research
Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease
CONCLUSIONS: Tenapanor is the first drug in its class that lowers hyperphosphatemia in ESKD patients through a novel mechanism of action involving paracellular inactive transport. Although more studies are needed, early results indicate that tenapanor may have a place in managing hyperphosphatemia in ESKD patients both as monotherapy and as an adjunct to existing phosphate binder therapy.PMID:35041802 | DOI:10.18433/jpps32284
Source: J Pharm Pharm Sci - January 18, 2022 Category: Drugs & Pharmacology Authors: Tiffany Lin Akram Al-Makki Brian Shepler Source Type: research
